Global mucopolysaccharidosis treatment market size was USD 1.98 billion in 2018 and is projected to reach USD 4.37 billion by 2026, exhibiting a CAGR…

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Mucopolysaccharidosis Treatment market.

Trusted Business Insights presents an updated and Latest Study on Mucopolysaccharidosis Treatment Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Mucopolysaccharidosis Treatment market during the forecast period (2019-2029). It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Mucopolysaccharidosis Treatment Market Size, Share & Industry Analysis, By Treatment (Enzyme Replacement Therapy (ERT), and Others), By Disease Type (Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type IV A, Mucopolysaccharidosis Type VI, and Others), By Route of Administration (Intravenous, and Intracerebroventricular (ICV)), By End User (Hospitals, Specialty Clinics, and Others), and Regional Forecast, 2020-2029(Includes COVID-18 Business Impact)

The global mucopolysaccharidosis treatment market size was USD 1.98 billion in 2018 and is projected to reach USD 4.37 billion by 2026, exhibiting a CAGR of 10.4% during the forecast period.

We have updated Mucopolysaccharidosis Treatment Market with respect to COVID-19 Impact. Inquire before buying

MPS, also known as mucopolysaccharidosis, refers to a group of key rare metabolic disorders which is caused by the absence, deficiency or malfunctioning of lysosomal enzymes called glycosaminoglycan (GAGs). This inability to completely down the sugar, leads to the abnormal accumulation of certain compounds such as dermatan sulfate, heparan sulfate, and keratan sulfate, which interferes with normal cell function of the body. One of the characteristic symptoms of MPS is the presence of severe neurological symptoms that are present in several types of MPS such as Hunter syndrome and Sanfilippo syndrome and a number of clinical stage companies are involved in the R&D of new therapeutics for the management of these symptoms.MARKET TRENDSIncreasing R&D for Rare Diseases to Drive the Market GrowthMarket trends present in the mucopolysaccharidosis (MPS) treatment market is the increasing number of pipeline candidates from major companies in the therapeutic area of rare diseases or orphan diseases. Since, mucopolysaccharidosis is considered to be a potentially serious orphan disease group, some prominent clinical stage biopharmaceutical companies such as ArmaGen and REGENXBIO Inc. are involved in the clinical trials for new therapeutics. This increasing initiatives into the development of rare diseases therapies is due to the fact that development of major blockbuster drugs is more possible in these rare diseases as compared to the conventional pharmaceutical portfolios. Another driving factor for this trend is that the pharmaceutical companies are mandated to conduct larger outcome studies for conventional medications or therapies. This is applicable for therapies to treat diseases such as heart disease and diabetes in comparison to rare disorders such as the several disease types of mucopolysaccharidosis. This is projected to further positively drive the mucopolysaccharidosis treatment market growth during the forecast period.


Need for Advanced Therapeutics Due to Unmet Clinical Needs and Better Treatment Outcomes to Propel Market GrowthThe lack of presence of a wide range of therapeutics for the patients, which has led to the creation of the monopoly of one type of therapy, enzyme replacement therapy is the most critical driver for the market growth. For instance, for the treatment of mucopolysaccharidosis type II (Hunter syndrome), Elaprase is the most commonly used therapeutic, an enzyme replacement therapy (ERT). This ERT is a prohibitively expensive therapy option and often patients from developing countries cannot easily access this therapeutic due to cost constraints. Other therapeutics for MPS treatment include Vimizim (elosulfase alfa) which is administered for the treatment of MPS IV A (Morquio syndrome) and which at the time of launch in the market is estimated to cost US$ 380,000 for the disorders annual treatment. Hence, due to the six-figure costs of most of the enzyme replacement therapy (ERT), the patients in the emerging countries such as India, often cannot afford these therapeutics despite increasing initiatives for improved access from various governments. Anticipated launches of cheaper alternatives and advanced therapeutics is anticipated to drive the growth of the global MPS treatment market during the forecast period.Another critical driving factor is the increasing need for advanced therapeutics due to unmet clinical needs and better treatment outcomes. During the current period therapeutics, such as Elaprase, and ALDURAZYME are not capable of crossing the blood-brain barrier, a key requirement for effective management of the disorder. So, these therapeutics are not able to appropriately address the neurological symptoms and complications of the patients of mucopolysaccharidosis (MPS), who are most severely affected. For instance, in the patients of Hunter syndrome with the most severe symptoms, which affects approximately two-thirds of the total patient population, the neurological symptoms are severely disabling. The therapeutics used currently are not able to treat the neurological symptoms, thus a significant proportion of the population remains in the need for appropriate treatment. This is anticipated to propel the demand for effective therapeutics which aid in the management of all types of the symptoms of the mucopolysaccharidosis and drive the growth of the MPS treatment market size during the forecast period.Increasing Number of Clinical Stage Candidates in R&D Pipelines of Major Players to Drive MarketThere is a significant number of pipeline candidates for the development of advanced therapeutics for an increasing number of rare disorders and the several types of mucopolysaccharidosis is one of the key disease groups for these companies due to the severity of the disease. According to the National Organization for Rare Disorders (NORD) (NORD), the prevalence of all disease types of mucopolysaccharidosis is estimated to be 1 in 25,000 births. In April 2019, it was reported that in Japan, an estimated 150 individuals suffered from mucopolysaccharidosis type II (Hunter syndrome). Such driving factors are further leading to the presence of prominent and important pipeline candidates. ArmaGen, Denali Therapeutics, and REGENXBIO Inc., all have pipeline candidates for the various types of MPS in various stages of clinical trials. The above factors combined with the need for advanced therapeutics is further anticipated to drive the demand for these therapeutics and stimulate the MPS market growth.MARKET RESTRAINTHigh Cost Therapeutics Coupled with Poorer Diagnosis Rates and Low Treatment Rates in Emerging Countries to Restrain the Market In recent times, globally due to sophistication in diagnostics, there is a higher prevalence of MPS in several countries which includes emerging regions such as Asia, there are certain factors that are restraining the widespread usage of these therapies. Due to the high costs associated with enzyme replacement therapies (ERT), which is the mainstay treatment for MPS, one of the major factors limiting the growth of the market is low levels treatment rates in emerging countries. This severely limits the number of patients undergoing treatment, and a significant proportion of the patients of MPS are left without treatment due to their inability to afford treatment. Often, these therapies are not available to the patients in the developing countries due to lack of awareness and also options for the payment of these therapies. The governments in these countries often do not have appropriate awareness regarding these diseases and do not adequately reimburse them. Another key limiting factor is the delays associated with the diagnosis of mucopolysaccharidosis. A study published in 2018, in the Orphanet Journal of Rare Diseases, indicated that there is a failure to shorten the diagnostic delay in the two ultra-orphan diseases of mucopolysaccharidosis types I and mucopolysaccharidosis type III. Factors as such are further expected to restrain the market growth.SEGMENTATIONBy Treatment AnalysisEnzyme Replacement Therapy (ERT) is Expected to Dominate the Global MarketBased on treatment, the global market is segmented into enzyme replacement therapy (ERT), and others. The primary treatment for lysosomal storage disorders, a group of disorders to which MPS belongs, is enzyme replacement therapy (ERT). These enzyme replacement therapies, aim to replace or generate the missing or deficient enzyme in the body, due to which mucopolysaccharidosis occurs. Hence, the enzyme replacement therapy (ERT) segment dominated the mucopolysaccharidosis treatment market share in 2018. The only major therapeutics approved by the regulatory agencies globally treatment of MPS, is enzyme replacement therapy (ERT). For example, in case of mucopolysaccharidosis type II (Hunter syndrome), the only two approved products are Elaprase and Hunterase which are both ERTs, and have been instrumental in the dominance of this segment in the global market.The others segment is anticipated to grow at a comparatively stronger CAGR. The mucopolysaccharidosis (MPS) treatment market growth during the forecast period is anticipated to be driven by the growing number of clinical trials involving the usage of the hematopoietic stem cell transplant (HSCT). Other than stem cell transplantation, a number of prominent clinical stage biopharmaceutical companies are conducting trials on gene therapy including Sangamo Therapeutics, which has a pipeline candidate for Hunter syndrome.By Disease Type Analysis To know how our report can help streamline your business, Speak to Analyst var get_chart_name1=

MPS II (Hunter Syndrome) to Dominate the Disease Type due to Presence of Key Products In terms of disease type, the market is segmented into mucopolysaccharidosis type I also known as Hurler syndrome/Hurler-Scheie syndrome/Scheie syndrome, mucopolysaccharidosis type II also known as Hunter syndrome, mucopolysaccharidosis type IV A also known as Morquio A syndrome, mucopolysaccharidosis Type VI also known as MaroteauxLamy syndrome, and others. The mucopolysaccharidosis type II (Hunter Syndrome) is expected to dominate the market due to the presence of key products such as Hunterase and Elaprase. Both of these products accounts for a significant portion of the market revenue share. The other segments in the global mucopolysaccharidosis treatment market which includes mucopolysaccharidosis type I, mucopolysaccharidosis type IV A and mucopolysaccharidosis Type VI, all of which have key products offerings attributable to them. Such factors are anticipated to drive the market during the forecast period.The others segment includes mucopolysaccharidosis type VII (Sly syndrome) whose product offering of MEPSEVII (vestronidase alfa-vjbk) is anticipated to register a strong growth rate during the forecast period. Growing prevalence of the mucopolysaccharidosis types, along with introduction of major enzyme replacement therapy (ERT) products in the market, is expected to drive the growth of the segment during the forecast period.By Route of Administration AnalysisPresence of Major Therapeutics in Intravenous Form to Aid Dominance of the SegmentIn terms of route of administration, the market is segmented into intravenous, and intracerebroventricular (ICV). The intravenous type is anticipated to account for the majority of the revenue share of the route of administration segment, because most of the therapeutics for MPS treatment are to be administered through intravenous injections only. For example, the most prominent therapeutic for Hunter syndrome, Elaprase is administered intravenously. Intravenous therapeutics holds a monopoly over the mucopolysaccharidosis treatment market and is anticipated to hold control over its market share in the forecast period.The only other approved therapeutic that is not in an intravenous form and the route of administration is intracerebroventricular (ICV), is Hunterase. Growing approvals in other countries of these therapeutic, along with anticipated introduction in other countries across the globe, is expected to drive the growth of the segment during the forecast period.By End User AnalysisIncreased Need for Administration of Therapeutics at Hospitals to Enable Dominance of the SegmentOn the basis of end user, the market is segmented into hospitals, specialty clinics, and others. The key factor aiding in the dominance of hospitals segment is that the therapeutics used in MPS treatment can often be administered by trained medical professionals who can administer these therapeutics in settings such as hospitals with care and proper guidelines. This allows for the proper adherence to the MPS treatment guidelines and administration of critical therapeutics which have to be administered intravenously, in a safe environment to manage the increased risk of infusion site infections.Growing number of specialty clinics, due to increasing need for specialist care of a higher degree for the treatment and management of several types of mucopolysaccharidosis (MPS) patients, are some of the major factors responsible for this segments dominance forecast period. Also, a number of these specialty clinics are based in the developed countries, resulting in a strong market revenue share. Also, the increasing government initiatives such as the Brazilian Governments initiative for the setting up of treatment guidelines is also anticipated to contribute to the segments growth.


segmentation(get_label12,get_values2,chartid);The mucopolysaccharidosis (MPS) treatment market size in North America stood at USD 1,019.4 million in 2018. Some of the characteristics of this market is higher diagnosis and treatment rates for a number of rare disorders, coupled with adequate reimbursement policies for these therapeutics. These factors, coupled with higher awareness among patient population towards advanced treatment options, increasing diagnostic sophistication, presence of significant clinical trials, and the presence of major clinical stage biopharmaceutical companies are their pipeline candidates, are responsible for highest share of the region in the global market. The market in Europe is anticipated to account for the second largest revenue share during the forecast period. The presence of key products in the region such as Elaprase and ALDURAZYME, is anticipated to drive the demand for MPS treatment in Europe during 2019-2026. Asia-Pacific is projected to register the highest CAGR during the forecast period. Anticipated launch of some therapeutics such as Hunterase in Japan in Asia Pacific, the upcoming product launches in the region due to increased regulatory applications for approvals, and the presence of a strong potential patient population base in the region, together are projected to fuel the mucopolysaccharidosis (MPS) treatment market growth in Asia Pacific during forecast period. The rest of the world market comprises of Latin America and the Middle East & Africa and is currently in nascent stage. However, developing healthcare infrastructure in these regions, increased government initiatives and growing awareness of rare disorders is projected to fuel the mucopolysaccharidosis treatment market demand during forecast period.KEY INDUSTRY PLAYERSKey Product Offerings and Core Focus on Mucopolysaccharidosis of Shire (Takeda Pharmaceutical Company Limited) and BioMarin, to Propel the Company to a Leading Position Competition landscape of mucopolysaccharidosis (MPS) treatment market depicts a competitive landscape dominated by a few key players. Shire (now owned by Takeda Pharmaceutical Company Limited), whose prominent product of Elaprase commands a strong revenue share, and BioMarin are some of the key market players. For example, the product offering of Shire (Takeda Pharmaceutical Company Limited) of Elaprase (idursulfase), its efficiency in terms of treatment outcomes and also its indispensability in treatment of MPS II, are prominent factors responsible for the dominance of the company in the mucopolysaccharidosis treatment. BioMarin has the key product offerings of ALDURAZYME, VIMIZIM, and NAGLAZYME in its product portfolio, covering three types of mucopolysaccharidosis.However, ArmaGen, and REGENXBIO Inc., are some of the prominent clinical stage biopharmaceutical companies such who have entered the clinical trials with their potential drug candidates. This is projected to positively impact the global market as these companies are poised to gain market share during the forecast period through key regulatory approvals.LIST OF KEY COMPANIES PROFILED :Shire (Takeda Pharmaceutical Company Limited)Denali TherapeuticsArmaGenREGENXBIO Inc.Sangamo TherapeuticsBioMarinLysogeneAbeona Therapeutics Inc.Ultragenyx PharmaceuticalGenzyme CorporationOthersKEY INDUSTRY DEVELOPMENTS:February 2020 Lysogene, a key clinical stage biopharmaceutical company, received the FDA fast track designation for the pipeline candidate of LYS-SAF302 gene therapy in MPS IIIA, also known as the Sanfilippo syndrome.April 2019 Abeona Therapeutics, a key integrated leader in cell and gene therapy development, received the FDA Fast Track Designation for their pipeline candidate of ABO-101 for the treatment of Sanfilippo syndrome type B or MPS IIIB.August 2018 Ultragenyx announced the approval of Mepsevii (vestronidase alfa) in Europe for the treatment of mucopolysaccharidosis VII, also known as Sly syndrome.REPORT COVERAGEThe mucopolysaccharidosis treatment market report provides a detailed analysis of the market and focuses on key aspects such as prevalence of key mucopolysaccharidosis types by key regions (2018), pipeline analysis, key industry developments, regulatory scenario- by key regions, overview of emerging treatments for mucopolysaccharidosis, and reimbursement scenario by key regions. Besides this, the report offers insights into the market trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the market over the recent years.

Report Scope & Segmentation

ATTRIBUTEDETAILSStudy Period 2015-2026Base Year 2018Forecast Period 2019-2026Historical Period 2015-2017Unit Value (USD billion)SegmentationBy TreatmentEnzyme Replacement Therapy (ERT)OthersBy Disease TypeMucopolysaccharidosis Type IMucopolysaccharidosis Type IIMucopolysaccharidosis Type IV AMucopolysaccharidosis Type VIOthersBy Route of Administration IntravenousIntracerebroventricular (ICV)By End User HospitalsSpecialty ClinicsOthersBy GeographyNorth America (U.S. and Canada)Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)Rest of the World

Looking for more? Check out our repository for all available reports on Mucopolysaccharidosis Treatment in related sectors.

Quick Read Table of Contents of this Report @ Mucopolysaccharidosis Treatment Market Size, Share & Industry Analysis, By Treatment (Enzyme Replacement Therapy (ERT), and Others), By Disease Type (Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type IV A, Mucopolysaccharidosis Type VI, and Others), By Route of Administration (Intravenous, and Intracerebroventricular (ICV)), By End User (Hospitals, Specialty Clinics, and Others), and Regional Forecast, 2020-2029(Includes COVID-18 Business Impact)

Trusted Business Insights Shelly Arnold Media & Marketing Executive Email Me For Any Clarifications Connect on LinkedIn Click to follow Trusted Business Insights LinkedIn for Market Data and Updates. US: +1 646 568 9797 UK: +44 330 808 0580

View post:
Global mucopolysaccharidosis treatment market size was USD 1.98 billion in 2018 and is projected to reach USD 4.37 billion by 2026, exhibiting a CAGR…